JP2007506715A - ガンマセクレターゼ阻害剤 - Google Patents
ガンマセクレターゼ阻害剤 Download PDFInfo
- Publication number
- JP2007506715A JP2007506715A JP2006527458A JP2006527458A JP2007506715A JP 2007506715 A JP2007506715 A JP 2007506715A JP 2006527458 A JP2006527458 A JP 2006527458A JP 2006527458 A JP2006527458 A JP 2006527458A JP 2007506715 A JP2007506715 A JP 2007506715A
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- alkyl
- optionally
- mmol
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 C[C@@](CC1CC(/C=C2)=C(C3)C/C(/*)=C/C2(C)O)[C@@]3C1=O Chemical compound C[C@@](CC1CC(/C=C2)=C(C3)C/C(/*)=C/C2(C)O)[C@@]3C1=O 0.000 description 2
- WGURHPWPMTUMAQ-YZZKKUAISA-N O=S(NCC(F)(F)F)(N[C@H]1[C@H]2Cc3cc(-c(nc4)c[n]4-c(cc4)ccc4F)ccc3C[C@@H]1CC2)=O Chemical compound O=S(NCC(F)(F)F)(N[C@H]1[C@H]2Cc3cc(-c(nc4)c[n]4-c(cc4)ccc4F)ccc3C[C@@H]1CC2)=O WGURHPWPMTUMAQ-YZZKKUAISA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Description
XはH、OH、C1−4アルコキシ、Cl又はFを表し;
Yは結合、O又はNR3を表し;
Arはハロゲン、CF3、CHF2、CH2F、NO2、CN、OCF3、C1−6アルキル及びC1−6アルコキシから独立して選択される0〜3個の置換基を各々もつフェニル又は6員環ヘテロアリールを表し;
R1はHを表すか;又はYがNR3を表す場合には、R1とR3は一緒になって−CH2−を表してもよく;
R2はH又は場合によりCN、C1−4アルコキシもしくは3個までのハロゲン原子で置換された炭素原子数1〜10の炭化水素基を表すか;R2は場合によりハロゲン、CF3、CHF2、CH2F、NO2、CN、OCF3、C1−6アルキル及びC1−6アルコキシから独立して選択される3個までの置換基をもつ5又は6員環ヘテロアリールを表すか;あるいはYがNR3を表す場合には、R2とR3は一緒になって場合によりハロゲン、CF3、CHF2、CH2F、NO2、CN、OCF3、C1−6アルキル及びC1−6アルコキシから独立して選択される3個までの置換基をもつ6員環までの複素環を形成してもよく;
R3はH又はC1−4アルキルを表すか、R2と一緒になって上記複素環を形成するか、あるいはR1と一緒になって−CH2−を形成し;
但しXがHであり、YがNR3を表し、R1とR3が一緒になって−CH2−を表す場合には、R2は2,2,2−トリフルオロエチル以外のものを表し;R1とR2が同時にHであることはない)の化合物又は医薬的に許容可能なその塩が提供される。
N−{(6S,9R,11R)−2−[1−(4−フルオロフェニル)−1H−イミダゾール−4−イル]−5,6,7,8,9,10−ヘキサヒドロ−6,9−メタノベンゾ[a][8]アヌレン−11−イル}−N’−(2,2,2−トリフルオロエチル)スルファミド
N−シクロブチル−N’−{(6S,9R,11R)−2−[1−(4−フルオロフェニル)−1H−1,2,4−トリアゾール−3−イル]−5,6,7,8,9,10−ヘキサヒドロ−6,9−メタノベンゾ[8]アヌレン−11−イル}スルファミド
N−{(6S,9R,11R)−2−[1−(4−フルオロフェニル)−1H−1,2,4−トリアゾール−3−イル]−5,6,7,8,9,10−ヘキサヒドロ−6,9−メタノベンゾ[8]アヌレン−11−イル}−N’−プロピルスルファミド
ジアステレオ異性体1,1H NMR(360MHz,CDCl3)δH 1.29(2H,m),1.45(3H,d,J=7.0),1.75(2H,m),2.48(2H,m),2.71(2H,m),3.17(1H,d,J=15.9),3.32(1H,m),3.35(2H,s),4.20(1H,m),4.74(1H,s),7.03(2H,m),7.17(1H,m)。
ジアステレオ異性体2,1H NMR(360MHz,CDCl3)δH 1.27(2H,m),1.46(3H,d,J=7.0),1.76(2H,m),2.46(2H,m),2.72(2H,m),3.21(1H,d,J=15.8),3.30(1H,d,J=15.8),3.35(2H,s),4.20(1H,m),4.62(1H,s),7.04(2H,m),7.17(1H,m)。
Claims (14)
- 式I:
XはH、OH、C1−4アルコキシ、Cl又はFを表し;
Yは結合、O又はNR3を表し;
Arはハロゲン、CF3、CHF2、CH2F、NO2、CN、OCF3、C1−6アルキル及びC1−6アルコキシから独立して選択される0〜3個の置換基を各々もつフェニル又は6員環ヘテロアリールを表し;
R1はHを表すか;又はYがNR3を表す場合には、R1とR3は一緒になって−CH2−を表してもよく;
R2はH又は場合によりCN、C1−4アルコキシもしくは3個までのハロゲン原子で置換された炭素原子数1〜10の炭化水素基を表すか;R2は場合によりハロゲン、CF3、CHF2、CH2F、NO2、CN、OCF3、C1−6アルキル及びC1−6アルコキシから独立して選択される3個までの置換基をもつ5又は6員環ヘテロアリールを表すか;あるいはYがNR3を表す場合には、R2とR3は一緒になって場合によりハロゲン、CF3、CHF2、CH2F、NO2、CN、OCF3、C1−6アルキル及びC1−6アルコキシから独立して選択される3個までの置換基をもつ6員環までの複素環を形成してもよく;
R3はH又はC1−4アルキルを表すか、R2と一緒になって上記複素環を形成するか、あるいはR1と一緒になって−CH2−を形成し;
但しXがHであり、YがNR3を表し、R1とR3が一緒になって−CH2−を表す場合には、R2は2,2,2−トリフルオロエチルを表さず;R1とR2が同時にHであることはない)の化合物又は医薬的に許容可能なその塩。 - Yが結合であり、R2が場合により3個までのフッ素もしくは塩素置換基をもつ炭素原子数6までの炭化水素であるか、又は場合により置換された5もしくは6員環ヘテロアリールである請求項2に記載の化合物。
- YがOであり、R2が場合により3個までのフッ素原子で置換された炭素原子数6までのアルキル、アルケニル、シクロアルキル又はシクロアルキルアルキルを表す請求項2に記載の化合物。
- YがNH又はNMeであり、R2が場合により3個までのフッ素原子で置換された炭素原子数6までのアルキル、アルケニル、シクロアルキル又はシクロアルキルアルキルを表す請求項2に記載の化合物。
- YがNR3を表し、R2とR3が複素環を形成する請求項2に記載の化合物。
- R2がH又は場合により3個までのハロゲン原子、CNもしくはC1−4アルコキシで置換された炭素原子数1〜10の炭化水素基を表す請求項7に記載の化合物。
- XがHである請求項1から8のいずれかに記載の化合物。
- Arがフェニル、モノハロフェニル、ジハロフェニル、トリハロフェニル、シアノフェニル、メチルフェニル、メトキシフェニル、トリフルオロメチルフェニル、トリフルオロメトキシフェニル、ピリジル、モノハロピリジル及びトリフルオロメチルピリジルから選択され、前記「ハロ」はフルオロ又はクロロを表す請求項1から9のいずれかに記載の化合物。
- 請求項1から10のいずれかに記載の化合物と医薬的に許容可能なキャリヤーを含有する医薬組成物。
- 人体の治療方法で使用するための請求項1から10のいずれかに記載の化合物。
- アルツハイマー病の治療又は予防用医薬の製造における請求項1から10のいずれかに記載の化合物の使用。
- 有効量の請求項1から10のいずれかに記載の化合物を患者に投与することを含むアルツハイマー病に罹患しているか又はその傾向のある患者の治療方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0322341A GB0322341D0 (en) | 2003-09-24 | 2003-09-24 | Therapeutic agents |
GB0322340A GB0322340D0 (en) | 2003-09-24 | 2003-09-24 | Therapeutic agents |
PCT/GB2004/003973 WO2005030731A1 (en) | 2003-09-24 | 2004-09-16 | Gamma-secretase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2007506715A true JP2007506715A (ja) | 2007-03-22 |
Family
ID=34395437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006527458A Pending JP2007506715A (ja) | 2003-09-24 | 2004-09-16 | ガンマセクレターゼ阻害剤 |
Country Status (7)
Country | Link |
---|---|
US (1) | US7514459B2 (ja) |
EP (1) | EP1667984B1 (ja) |
JP (1) | JP2007506715A (ja) |
AT (1) | ATE509917T1 (ja) |
AU (1) | AU2004276050B2 (ja) |
CA (1) | CA2539042A1 (ja) |
WO (1) | WO2005030731A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014520851A (ja) * | 2011-07-12 | 2014-08-25 | ダウ アグロサイエンシィズ エルエルシー | 殺有害生物剤組成物およびこれに関連した方法 |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
WO2006050359A2 (en) | 2004-11-02 | 2006-05-11 | Northwestern University | Pyridazine compounds and methods |
ES2382814T3 (es) | 2005-05-17 | 2012-06-13 | Merck Sharp & Dohme Ltd. | Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer |
US8242103B2 (en) | 2005-05-19 | 2012-08-14 | Merck Sharp & Dohme Limited | Sulphamides for treatment of cancer |
EP1996182A4 (en) | 2006-02-27 | 2009-08-12 | Univ Johns Hopkins | CANCER TREATMENT WITH GAMMA SECRETASE INHIBITORS |
WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
WO2008076556A2 (en) | 2006-11-15 | 2008-06-26 | Massachusetts Eye & Ear Infirmary | Generation of inner ear cells |
SI2091948T1 (sl) | 2006-11-30 | 2012-07-31 | Probiodrug Ag | Novi inhibitorji glutaminil ciklaze |
EP2121633A2 (en) | 2007-02-12 | 2009-11-25 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
EP2481408A3 (en) | 2007-03-01 | 2013-01-09 | Probiodrug AG | New use of glutaminyl cyclase inhibitors |
DK2142514T3 (da) | 2007-04-18 | 2015-03-23 | Probiodrug Ag | Thioureaderivater som glutaminylcyclase-inhibitorer |
WO2009128057A2 (en) | 2008-04-18 | 2009-10-22 | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al | Psycho-pharmaceuticals |
CA2743436C (en) | 2008-11-24 | 2017-10-31 | Massachusetts Eye & Ear Infirmary | Pathways to generate hair cells |
US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
AU2010294214B2 (en) | 2009-09-11 | 2015-05-07 | Vivoryon Therapeutics N.V. | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
WO2011046771A1 (en) | 2009-10-14 | 2011-04-21 | Schering Corporation | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF |
JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
AU2011226074B2 (en) | 2010-03-10 | 2015-01-22 | Vivoryon Therapeutics N.V. | Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5) |
EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
WO2011163330A1 (en) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
CA2805265A1 (en) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina) |
WO2012024170A2 (en) | 2010-08-17 | 2012-02-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US8946216B2 (en) | 2010-09-01 | 2015-02-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
EP2615916B1 (en) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel erk inhibitors |
WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
JP6050264B2 (ja) | 2011-03-16 | 2016-12-21 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
US20150299696A1 (en) | 2012-05-02 | 2015-10-22 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
AU2013312358B2 (en) | 2012-09-07 | 2018-08-09 | Massachusetts Eye & Ear Infirmary | Treating hearing loss |
WO2014052563A2 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
MX363243B (es) | 2012-11-28 | 2019-03-14 | Merck Sharp & Dohme | Composiciones para tratar cáncer y usos de dichas composiciones. |
RU2690663C2 (ru) | 2012-12-20 | 2019-06-05 | Мерк Шарп И Доум Корп. | Замещенные имидазопиридины в качестве ингибиторов hdm2 |
US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
WO2016022776A2 (en) | 2014-08-06 | 2016-02-11 | Massachusetts Eye And Ear Infirmary | Increasing atoh1 life to drive sensorineural hair cell differentiantion |
WO2017096233A1 (en) | 2015-12-04 | 2017-06-08 | Massachusetts Eye And Ear Infirmary | Treatment of hearing loss by inhibition of casein kinase 1 |
AU2017212655B2 (en) | 2016-01-29 | 2024-01-18 | Decibel Therapeutics, Inc. | Expansion and differentiation of inner ear supporting cells and methods of use thereof |
WO2017200762A2 (en) | 2016-05-16 | 2017-11-23 | The General Hospital Corporation | Human airway stem cells in lung epithelial engineering |
JP6904612B2 (ja) | 2016-12-16 | 2021-07-21 | パイプライン セラピューティクス, インコーポレイテッド | 蝸牛シナプス障害を処置する方法 |
PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
EP3833668A4 (en) | 2018-08-07 | 2022-05-11 | Merck Sharp & Dohme Corp. | PRMT5 INHIBITORS |
WO2020033284A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
AU2020408148A1 (en) | 2019-12-17 | 2022-06-16 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
WO2024049931A1 (en) | 2022-09-02 | 2024-03-07 | Merck Sharp & Dohme Llc | Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001070677A1 (en) * | 2000-03-20 | 2001-09-27 | Merck Sharp & Dohme Limited | Sulphonamido-substituted bridged bicycloalkyl derivatives |
WO2002036555A1 (en) * | 2000-11-02 | 2002-05-10 | Merck Sharp & Dohme Limited | Sulfamides as gamma-secretase inhibitors |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK145080A (da) * | 1979-04-04 | 1980-10-05 | Merck Sharp & Dohme | Fremgangsmaade til fremstilling af aminoderivater af 2-hydroxy-6,9-methano-11-amino-5,6,7,8,9,10-hexahydrobenzocycloocten |
US4341904A (en) * | 1980-02-19 | 1982-07-27 | Merck & Co., Inc. | Derivatives of 2-hydroxy-6,9-methano-11-amino-5,6,7,8,9,10-hexahydro-benzocyclooctene |
CA2276278C (en) | 1997-02-27 | 2009-04-07 | Takeda Chemical Industries, Ltd. | Amine compounds, their production and use |
GB0119152D0 (en) | 2001-08-06 | 2001-09-26 | Merck Sharp & Dohme | Therapeutic agents |
GB0209995D0 (en) * | 2002-05-01 | 2002-06-12 | Merck Sharp & Dohme | Therapeutic agents |
GB0209997D0 (en) | 2002-05-01 | 2002-06-12 | Merck Sharp & Dohme | Therapeutic agents |
GB0209991D0 (en) | 2002-05-01 | 2002-06-12 | Merck Sharp & Dohme | Therapeutic agents |
WO2003093252A1 (en) | 2002-05-01 | 2003-11-13 | Merck Sharp & Dohme Limited | Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase |
GB0225474D0 (en) * | 2002-11-01 | 2002-12-11 | Merck Sharp & Dohme | Therapeutic agents |
GB0225475D0 (en) | 2002-11-01 | 2002-12-11 | Merck Sharp & Dohme | Therapeutic agents |
GB0326039D0 (en) * | 2003-11-07 | 2003-12-10 | Merck Sharp & Dohme | Therapeutic agents |
-
2004
- 2004-09-16 CA CA002539042A patent/CA2539042A1/en not_active Abandoned
- 2004-09-16 JP JP2006527458A patent/JP2007506715A/ja active Pending
- 2004-09-16 AU AU2004276050A patent/AU2004276050B2/en not_active Ceased
- 2004-09-16 US US10/571,717 patent/US7514459B2/en not_active Expired - Fee Related
- 2004-09-16 AT AT04768519T patent/ATE509917T1/de not_active IP Right Cessation
- 2004-09-16 WO PCT/GB2004/003973 patent/WO2005030731A1/en active Application Filing
- 2004-09-16 EP EP04768519A patent/EP1667984B1/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001070677A1 (en) * | 2000-03-20 | 2001-09-27 | Merck Sharp & Dohme Limited | Sulphonamido-substituted bridged bicycloalkyl derivatives |
WO2002036555A1 (en) * | 2000-11-02 | 2002-05-10 | Merck Sharp & Dohme Limited | Sulfamides as gamma-secretase inhibitors |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014520851A (ja) * | 2011-07-12 | 2014-08-25 | ダウ アグロサイエンシィズ エルエルシー | 殺有害生物剤組成物およびこれに関連した方法 |
Also Published As
Publication number | Publication date |
---|---|
ATE509917T1 (de) | 2011-06-15 |
WO2005030731A1 (en) | 2005-04-07 |
AU2004276050B2 (en) | 2010-02-25 |
CA2539042A1 (en) | 2005-04-07 |
EP1667984B1 (en) | 2011-05-18 |
AU2004276050A1 (en) | 2005-04-07 |
EP1667984A1 (en) | 2006-06-14 |
US20060293373A1 (en) | 2006-12-28 |
US7514459B2 (en) | 2009-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1667984B1 (en) | Gamma-secretase inhibitors | |
JP4714686B2 (ja) | 新規のγ−セクレターゼ阻害剤 | |
US7435748B2 (en) | Gamma-secretase inhibitors | |
JP4536517B2 (ja) | γ−セクレターゼ阻害剤としてのスルホンアミド、スルファメート及びスルファミド | |
EP1611129B1 (en) | Cyclic sulfamides for inhibition of gamma-secretase | |
US8338437B2 (en) | Amines as small molecule inhibitors | |
EP1223170B1 (en) | Pyrimidine-5-carboxamide compounds, process for producing the same and use thereof | |
AU2018217488B2 (en) | Aminotriazolopyridines as kinase inhibitors | |
EP3209651B1 (en) | Carbazole derivatives | |
JP2008533120A (ja) | 5−ht2a拮抗薬としてのアリールスルホニルベンゾ縮合複素環 | |
MX2007002308A (es) | Derivados arilsulfonilestilbeno para el tratamiento del insomnio y afecciones relacionadas. | |
CA3127786A1 (en) | Gpr35 modulators | |
EP1641756B1 (en) | 4-arylsulphonylpiperidine derivatives for antagonism of the 5-ht2a receptor | |
JP2001233875A (ja) | ピリミジン−5−カルボキサミド化合物、その製造法およびその用途 | |
TW201627290A (zh) | 具有抗疼痛之多重模式活性的哌衍生物 | |
NZ718251B2 (en) | Piperazine derivatives and the use thereof as medicament |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070822 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101130 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110222 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110301 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111025 |